Compare FLWS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLWS | ARMP |
|---|---|---|
| Founded | 1976 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.3M | 199.7M |
| IPO Year | 1999 | 1996 |
| Metric | FLWS | ARMP |
|---|---|---|
| Price | $2.63 | $3.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | ★ 345.2K | 105.4K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,151,921,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.37 | $2.75 |
| 52 Week High | $5.23 | $14.98 |
| Indicator | FLWS | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 40.48 | 37.82 |
| Support Level | $2.39 | $2.75 |
| Resistance Level | $3.02 | $5.63 |
| Average True Range (ATR) | 0.14 | 0.33 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 31.76 | 20.00 |
1-800-Flowers.com Inc is a provider of gifts designed to help customers express, connect, and celebrate. The company's e-commerce business platform features all brands, including 1-800-Flowers.com, 1-800-Baskets.com, Cheryl's Cookies, Harry and David, PersonalizationMall.com, Shari's Berries, FruitBouquets.com, Moose Munch, The Popcorn Factory, Wolferman's Bakery, Stock Yards, and Simply Chocolate. The company's business segments are; Consumer Floral and Gifts, BloomNet, and Gourmet Foods & Gift Baskets. The maximum revenue for the company is generated from its Gourmet Foods & Gift Baskets segment.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.